SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.

Trial Details

NCT ID
NCT07080619
Phase
PHASE2
Sponsor
Tianjin ConjuStar Biologics Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • SC-101
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age between 18 and 75 years (inclusive), regardless of gender.
  • ECOG performance status of 0-1.
  • Expected survival of more than 3 months, as assessed by the investigator.
  • Fertile participants must agree to use contraception.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →